Evidence map›Paper›PMID 29955664›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2018

Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine.

Maurizio Severino, Mithula Sivasaravanaparan, Louise Ø Olesen, Christian U von Linstow, Athanasios Metaxas, Elena V Bouzinova, Asif Manzoor Khan, Kate L Lambertsen, Alicia A Babcock, Jan Bert Gramsbergen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Maurizio SeverinoDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Mithula SivasaravanaparanDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Louise Ø OlesenCenter of Psychiatric Research, Aarhus University Hospital, Risskov, Denmark.
Christian U von LinstowDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Athanasios MetaxasDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Elena V BouzinovaCenter of Psychiatric Research, Aarhus University Hospital, Risskov, Denmark.
Asif Manzoor KhanDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Kate L LambertsenDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Alicia A BabcockDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Jan Bert GramsbergenDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
Ove WiborgCenter of Psychiatric Research, Aarhus University Hospital, Risskov, Denmark.
Bente FinsenDepartment of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment with selective serotonin reuptake inhibitors has been suggested to mitigate amyloid-β (Aβ) pathology in Alzheimer's disease, in addition to an antidepressant mechanism of action.

methodsWe investigated whether chronic treatment with paroxetine, a selective serotonin reuptake inhibitor, mitigates Aβ pathology in plaque-bearing double-transgenic amyloid precursor protein (APP)

resultsContrary to our hypothesis, paroxetine therapy did not mitigate Aβ pathology, and depletion of brain serotonin did not exacerbate Aβ pathology. However, chronic paroxetine therapy increased mortality in APP DISCUSSION: Our results question the ability of selective serotonin reuptake inhibitor therapy to ameliorate established Aβ pathology. The severe adverse effect of paroxetine may discourage its use for disease-modifying purposes in Alzheimer's disease.

Indexed as

[3H]DASB5,7-dihydroxytryptamineAlzheimer's diseaseAutoradiographyCerebral amyloidosisMonoamineNeocortexSelective serotonin reuptake inhibitorSerotoninSERT occupancyStereologyTransgenic mouse model

Identifiers

PMID29955664
PMCPMC6021554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.